Yikun Wang

Dr. Yikun Wang


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 April 2025 in Molecular Cancer
Verified
Journal Article
Open access
PDF file
YMYuan Mao
Yuan Mao
DSDangang Shangguan
Dangang Shangguan
QHQi Huang
Qi Huang
LXLing Xiao
Ling Xiao
DCDongsheng Cao
Dongsheng Cao
YWYikun Wang
Yikun Wang
Drug resistance is one of the main reasons for cancer treatment failure, leading to a rapid recurrence/disease progression of the cancer. Recently, artificial intelligence (AI) has empowered physicians to use its powerful data processing and pattern recognition capabilities to extract and mine valuable drug resistance information from large amounts of clinical or omics data, to study drug resistance mechanisms, to evaluate and predict drug resistance, and to develop innovative therapeutic strategies to reduce drug resistance. In this review, we proposed a feasible workflow for incorporating AI into tumor drug resistance research, highlighted current AI-driven tumor drug resistance applications, and discussed the opportunities and challenges encountered in the process. Based on a comprehensive literature analysis, we systematically summarized the role of AI in tumor drug resistance research, including drug development, resistance mechanism elucidation, drug sensitivity prediction, combination therapy optimization, resistance phenotype identification, and clinical biomarker discovery. With the continuous advancement of AI technology and rigorous validation of clinical data, AI models are expected to fuel the development of precision oncology by improving efficacy, guiding therapeutic decisions, and optimizing patient prognosis. In summary, by leveraging clinical and omics data, AI models are expected to pioneer new therapy strategies to mitigate tumor drug resistance, improve efficacy and patient survival, and provide novel perspectives and tools for oncology treatment.

30 December 2022 in Cancers
Verified
Journal Article
Open access
PDF file
Shuang XiaShuang Xia
Shuang Xia
HGHui Gong
Hui Gong
YZYichang Zhao
Yichang Zhao
LGLin Guo
Lin Guo
YWYikun Wang
Yikun Wang
MYMiao Yan
Miao Yan
Background: Although some sepsis cases were reported with immune checkpoint inhibitors (ICIs) in clinical trials, the link between pulmonary sepsis and ICIs remains mostly unknown. We aim to investigate the association between pulmonary sepsis and ICIs, and to describe the clinical features. Methods: A disproportionality analysis was performed using FAERS data and compared rates of pulmonary sepsis in cancer patients receiving ICIs vs. other drug regimens (such as chemotherapy and targeted therapy). Associations between ICIs and sepsis were assessed using reporting odds ratios (ROR) and information component (IC). We also detected drug interaction signals based on the Ω shrinkage measure. Age and gender distribution were compared between pulmonary sepsis and all adverse events associated with ICIs. Results: We identified 120 reports of pulmonary sepsis associated with ICIs between Q1, 2011 to Q3, 2021. A total of 82 of 120 (68.3%) patients on ICIs suffered from pulmonary sepsis and progressed to death. In addition, there is no significant difference in age and gender in the occurrence of pulmonary sepsis in cancer patients on ICIs. Overall ICIs, nivolumab, and atezolizumab still have a significant signal of pulmonary sepsis (ROR025 > 1, IC025 > 0, p < 0.001) compared with targeted therapy (such as tyrosine kinase inhibitors) or chemotherapy. Co-administration of ICIs and glucocorticoids or proton pump inhibitors synergistically increased the risk of pulmonary sepsis (Ω025 > 0). Conclusions: Our study suggested ICIs, especially nivolumab and atezolizumab, tended to increase the risk of pulmonary sepsis more than other anticancer regimens. Clinicians should be vigilant in the prevention and management of pulmonary sepsis during ICIs therapy.

1 December 2022 in Drug Metabolism Reviews
Verified
Journal Article
Closed access
MYMiao Yan
Miao Yan
WLWenqun Li
Wenqun Li
WLWen-Bo Li
Wen-Bo Li
QHQi Huang
Qi Huang
JLJing Li
Jing Li
YWYikun Wang
Yikun Wang
At present, receptor tyrosine kinase signaling-related pathways have been successfully mediated to inhibit tumor proliferation and promote anti-angiogenesis effects for cancer therapy. Tyrosine kinase inhibitors (TKIs), a group of novel chemotherapeutic agents, have been applied to treat diverse malignant tumors effectively. However, the latent toxic and side effects of TKIs, such as hepatotoxicity and cardiotoxicity, limit their use in clinical practice. Metabolic activation has the potential to lead to toxic effects. Numerous TKIs have been demonstrated to be transformed into chemically reactive/potentially toxic metabolites following cytochrome P450-catalyzed activation, which causes severe adverse reactions, including hepatotoxicity, cardiotoxicity, skin toxicity, immune injury, mitochondria injury, and cytochrome P450 inactivation. However, the precise mechanisms of how these chemically reactive/potentially toxic species induce toxicity remain poorly understood. In addition, we present our viewpoints that regulating the production of reactive metabolites may decrease the toxicity of TKIs. Exploring this topic will improve understanding of metabolic activation and its underlying mechanisms, promoting the rational use of TKIs. This review summarizes the updated evidence concerning the reactive metabolites of TKIs and the associated toxicities. This paper provides novel insight into the safe use of TKIs and the prevention and treatment of multiple TKIs adverse effects in clinical practice.

17 March 2026 in Chinese Medicine
Verified
Journal Article
Open access
PDF file
YMYuan Mao
Yuan Mao
LHLiWen Huang
LiWen Huang
HLHongPing Long
HongPing Long
Qi HuangQi Huang
Qi Huang
FKFenghua Kang
Fenghua Kang
YWYikun Wang
Yikun Wang
Triptolide, a bioactive triepoxide diterpenoid extracted from Tripterygium wilfordii Hook. f., has demonstrated broad pharmacological activities and significant toxicities. Mechanistically, triptolide has exerted therapeutic effects by regulating programmed cell death (PCD) through multiple pathways; however, its toxic reactions have been closely associated with this process. This review systematically summarizes the molecular mechanisms by which triptolide regulated various forms of PCD and its application progress in disease treatment, including apoptosis, autophagy, pyroptosis, ferroptosis, cuproptosis, necroptosis, and PANoptosis. A plethora of extant studies have revealed that triptolide exerted a regulatory effect on the PCD networks by intervening in multiple important signaling pathways and their key signaling nodes. Nevertheless, due to its poor target specificity, triptolide has resulted in multi-organ toxicities, which has in turn limited its clinical translation. Nano-delivery systems have explored as a potential strategy to mitigate the toxicity and improve the efficacy of triptolide by enhancing its tissue targeting (Specific nanocarriers can increase LD 50 from 0.48 to 0.88 mg/kg). Furthermore, key pharmacodynamic evidences from triptolide’s current clinical studies are limited, necessitating the elucidation of precise target sites and the advancement of standardized clinical trials. This review systematically integrates the pleiotropic pharmacological activities and multiple-organ toxicities of triptolide from a PCD perspective, providing novel insights and theoretical references for overcoming its clinical translation barriers. Graphical Abstract

19 May 2026 in Nucleic Acids Research
Verified
Journal Article
Open access
YZYiling Zhou
Yiling Zhou
SYSen Yang
Sen Yang
XWXiaoli Wang
Xiaoli Wang
YHYuanhang He
Yuanhang He
YTYao Tian
Yao Tian
DCDongsheng Cao
Dongsheng Cao
CYP450 (cytochrome P450)-mediated drug metabolism is a critical determinant of pharmacokinetics and clinical safety, making comprehensive metabolic profiling essential for rational drug discovery. Here, we present DeepCYP (https://deepcyp.scbdd.com), a freely accessible deep-learning web server for end-to-end CYP450 metabolic profiling. Trained on an expanded dataset and a mechanism-based reaction rule library, DeepCYP uses a multi-task graph neural network (GNN) combined with multi-scale descriptors. Operating directly on 2D molecular graphs, this architecture bridges the entire “pathway-site-product” continuum across nine major CYP isoforms (CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, and CYP3A4) within a unified pipeline. Benchmarking demonstrates that DeepCYP outperforms established tools, including FAME3, SMARTCyp, and BioTransformer 3.0, improving Top-1 and Top-2 ranking metrics by over 10%. Furthermore, the server supports high-throughput batch processing, capable of evaluating ~280 molecules per minute. DeepCYP also enhances interpretability through an interactive visualization interface, featuring susceptibility radar charts and dynamic transformation tables. By translating abstract predictions into biological insights, DeepCYP provides a practical tool to accelerate lead optimization and mitigate toxicity risks.

24 June 2026 in Frontiers in Nutrition
Verified
Journal Article
Open access
PDF file
ZYZi-Yu Yan
Zi-Yu Yan
XWXi-Fan Wei
Xi-Fan Wei
GDGui-Ming Deng
Gui-Ming Deng
WYWen-Bo Yang
Wen-Bo Yang
RGRui Gui
Rui Gui
YWYikun Wang
Yikun Wang
Functional sweet tea refers to tea beverages with health benefits and sweetness made from natural sweet plants, which has shown a promising potential for the prevention and treatment of various chronic metabolic diseases. However, no comprehensive catalogs of sweet tea have been reported, and the systematic synthesis of their species, distribution, life forms, and health benefits is lacking. In this review, we firstly define scientific concept functional sweet tea, referred to tea beverages with health benefits and sweetness made from natural sweet plants. A total of 22 functional sweet tea plants in China and 27 reported functional sweet components is firstly compiled, which not only standardizes academic terminology but also directly facilitates market growth of the sweet tea industry. Sweet components show strong potential on preventing hyperglycaemia, hyperlipidaemia, hypertension, hyperuricaemia, liver disease through facilitation of glycolipid metabolism, anti-inflammatory and antioxidant pathways, targeting multiple key mediators such as AMPK, SGLT, Nrf2, and intestinal flora. This review provides new insights into the prevention and management of various metabolic diseases through sweet tea, and holds important theoretical and practical significance for the development of functional foods, the industrialization of natural sweeteners, and the optimization of prevention and management strategies for metabolic diseases.